- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02178748
Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents (TB036)
A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents
Mycobacterium tuberculosis (M. tb) is a pathogen with worldwide distribution which infects humans causing tuberculosis (TB), a transmissible disease resulting in very high mortality and morbidity; development of an effective vaccine is a global health priority.
Over a billion people worldwide are infected with one or more helminths. Helminths are parasitic worms, of which Schistosoma mansoni is one species. There is some evidence that helminth infection may affect a person's response to a vaccine. In this trial the investigators hope to investigate whether Schistosoma mansoni infection affects adolescents' responses to a candidate TB vaccine called MVA85A, as adolescents are a crucial target group for an effective TB vaccine.
Přehled studie
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Entebbe, Uganda
- MRC/UVRI Uganda Research Unit on AIDS
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria
Participants must meet all of the following criteria to enter the trial:
- Healthy adolescents aged 12-17 years (both male and female)
- Resident in the study area for the duration of the study period
- Confirmation of prior vaccination with BCG not less than 6 months prior to projected study vaccination date (by visible BCG scar on examination or written documentation)
- No relevant findings in medical history or on physical examination
- Written informed consent by parent or guardian
- Written informed assent by subject
- Refrain from blood donation during the trial
- Agree to avoid pregnancy for the duration of the trial (female only)
- Able and willing (in the Investigator's opinion) to comply with all the study requirements
- Stool sample negative for S. mansoni (group 1) or positive for S. mansoni infection (group 2), based on the results of the Kato Katz stool analysis
- Willing to delay treatment for schistosomiasis for at least one month (group 2)
Exclusion Criteria
Participants may not enter the trial if ANY of the following apply:
- Clinical, radiological, or laboratory evidence of current active TB disease
- Laboratory evidence at screening of latent M. tb infection as indicated by a positive ELISPOT response to ESAT6 or CFP10 antigens
- Previous treatment for active or latent tuberculosis infection
- Shared a residence within one year prior to day 0 with an individual on anti-tuberculosis treatment or with culture or smear-positive pulmonary tuberculosis
- Received a TST within 90 days prior to day 0
- Clinically significant history of skin disorder, allergy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness, drug or alcohol abuse
- History of serious psychiatric condition or disorder
- Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents within 2 months prior to enrolment
- History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the study vaccine, including eggs
- Any abnormality of screening blood or urine tests that is deemed to be clinically significant or that may compromise the safety of the volunteer in the study
- Positive HBsAg, HCV or HIV antibodies
- Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the study vaccine for 30 days prior to dosing with the study vaccine, or planned use during the study period
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date
- Female currently lactating, confirmed pregnancy or intention to become pregnant during the trial period
- Screening blood sample positive for malaria or Mansonella perstans by microscopy
- Schistosoma mansoni infection intensity greater than 2000 eggs per gram of stool
- Any of the three screening stool samples positive for any helminths on Kato Katz examinations or for S. mansoni or Strongyloides stercoralis by PCR (group 1); or any of the three screening stool samples positive for helminths other than S. mansoni on Kato Katz examinations or for Strongyloides stercoralis by PCR (group 2)
- Screening urine sample positive for S. mansoni infection (group 1)
- Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the subject at risk or may influence the result of the trial or may affect the subject's ability to participate in the trial
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Group 1
Group 1 (Schistosoma mansoni uninfected): 12-24 BCG-vaccinated volunteers with no helminth infection.
Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
|
Single dose of 1x10^8pfu MVA85A intramuscular vaccination
Ostatní jména:
|
Experimentální: Group 2
Group 2 (Schistosoma mansoni infected): 12-24 BCG-vaccinated volunteers with helminth infection.
Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
|
Single dose of 1x10^8pfu MVA85A intramuscular vaccination
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
T cell immunogenicity by gamma-interferon ELISPOT of Ag85A response.
Časové okno: 8 weeks
|
To compare T cell immunogenicity in adolescents with and without S. mansoni infection.
|
8 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Evaluation of cytokines in supernatant of stimulated cells using Luminex and flow cytometry of Ag85A response.
Časové okno: 8 weeks
|
Effects of S. mansoni infection on other aspects of the immune response following MVA85A immunisation.
|
8 weeks
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Actively and passively collected data on adverse events.
Časové okno: 8 weeks
|
To assess the safety of MVA85A vaccination in BCG-vaccinated African adolescents aged 12-17 years.
|
8 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Alison Elliot, MRC/UVRI and LSHTM Uganda Research Unit
Publikace a užitečné odkazy
Obecné publikace
- Wajja A, Namutebi M, Apule B, Oduru G, Kiwanuka S, Akello M, Nassanga B, Kabagenyi J, Mpiima J, Vermaak S, Lawrie A, Satti I, Verweij J, Cose S, Levin J, Kaleebu P, Tukahebwa E, McShane H, Elliott AM. Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. Wellcome Open Res. 2018 Sep 19;3:121. doi: 10.12688/wellcomeopenres.14736.1. eCollection 2018.
- Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, Elliott AM, McShane H. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial. PLoS Negl Trop Dis. 2017 May 4;11(5):e0005440. doi: 10.1371/journal.pntd.0005440. eCollection 2017 May.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- TB036
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Tuberkulóza
-
University Children's Hospital BaselUniversity Hospital, Geneva; University Hospital Inselspital, Berne; Kantonsspital... a další spolupracovníciNábor
-
National Institute of Allergy and Infectious Diseases...DokončenoMycobacterium tuberculosisBrazílie
-
The University of Texas Health Science Center,...National Institute of Allergy and Infectious Diseases (NIAID)DokončenoMycobacterium tuberculosisSpojené státy, Kolumbie, Mexiko
-
Johns Hopkins UniversityUkončeno
-
National Institute of Allergy and Infectious Diseases...Dokončeno
-
National Institute of Allergy and Infectious Diseases...Dokončeno
-
François SpertiniUniversity of OxfordDokončenoTuberkulóza | Mycobacterium Tuberculosis, ochrana protiŠvýcarsko
-
Region SkaneNáborLatentní tuberkulóza | Mycobacterium tuberculosis | Přetrvávající infekceŠvédsko
-
Serum Institute of India Pvt. Ltd.Vakzine Projekt Management GmbHAktivní, ne náborInfekce Mycobacterium TuberculosisGabon, Keňa, Jižní Afrika, Tanzanie, Uganda
-
Assistance Publique - Hôpitaux de ParisDokončenoKostní a osteoartikulární infekce způsobené MDR kmeny M. TuberculosisFrancie